We have been following the progress of small molecule inhibitors targeting the menin-chromatin interaction which leads to NPM1 mutated or MLL-rearranged acute leukemias for over a year now.

In the beginning there was Syndax and Kura Oncology, now there’s a growing list of other companies entering this niche, both big and small.

In this post we take a look at what’s new in the landscape and also explore Syndax’s updated phase 1 data announced this morning.

Where are things headed and what can we learn about the latest data drop?

To learn more about the Menin NPM1-MLLr niche and get a heads up on our oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by